Please assess the completion status of the following clinical trial:

Trial Title: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of any of the following:~  * Peripheral T-cell lymphoma not otherwise specified (PTCL-U),(IPI \>2)~ * Angioimmunoblastic T-cell lymphoma (AILT) (IPI \>2)~ * Non-primary cutaneous Alk-1-negative anaplastic large cell lymphoma~ * Extranodal natural killer (NK)/T lymphoma (Excluding stage I/II nasal disease)~ * Blastic NK cell lymphoma~ * Enteropathy type T-cell lymphoma~ * Cutaneous panniculitis-like T-cell lymphoma~ * Hepatosplenic T-cell lymphoma~* Measurable or assessable disease is not required.~* Age ≥ 18 and ≤ 70 years~* Previously untreated or 1 prior cycle of chemotherapy~* Creatinine \< 2.0 mg/dL~* Total bilirubin \< 2.0 mg/dL, aspartate aminotransferase (AST) \< 3x upper limit of normal~* Patients who test positive for Hepatitis B surface Ag (HepBSAg) or Hepatitis C antibody (HepCAb) are eligible provided all of the following criteria are met:~  * bilirubin ≤ 2 x upper limit of normal;~ * aspartate aminotransferase (AST) ≤ 3 x upper limit of normal;~ * liver biopsy demonstrates ≤ grade 2 fibrosis and no cirrhosis.~Hepatitis B surface Ag(+) patients will be treated with lamivudine (3TC) or investigator's preferred antiviral regimen throughout protocol therapy and for 6-12 months thereafter.~* Neutrophils ≥ 1000/microlitre (uL) platelets \> 100,000/uL~* HIV-negative~* Left ventricular ejection fraction (LVEF) of ≥ 45%~* No known hypersensitivity to denileukin diftitox or any of its components: diptheria toxin, interleukin-2, or excipients~* Non-pregnant, non-nursing: Treatment under this protocol would expose an unborn child to significant risks. Women and men of reproductive potential should agree to use an effective means of birth control.~* Patients with a currently active second malignancy, other than non-melanoma skin cancers are not eligible. (This includes Waldenstrom's Macroglobulinemia, since such patents have experienced transient increases inImmunoglobulin M (IgM) following initiation of rituximab, with the potential for hyperviscosity syndrome requiring plasmapheresis). Patients are not considered to have a currently active malignancy if they have completed anti-cancer therapy, and are considered by their physician to be at less than 30% risk of relapse.~Exclusion Criteria:~* PTCL-U / AILT with IPI 0 or 1 Extranodal NK/T nasal stage I/II T-lymphoblastic lymphoma Adult T-cell leukemia/lymphoma~* Adult T-cell leukemia/lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Plan (Type: EXPERIMENTAL): (1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5

Based on this trial design, predict the completion outcome and termination type (if applicable).